The global subcutaneous drug delivery devices market size was estimated to be USD 31.63 billion in 2023 and is expected to reach at USD 94.58 billion by 2034 with a CAGR of 10.47% during the forecast period 2024-2034. The presence of cutting-edge minimally invasive drug delivery devices, an increase in the occurrence of diabetes and Cardiovascular Diseases (CVD), a rise in the development of biologic drugs, an upswing in vaccination numbers, a growing elderly population, an elevated emphasis on innovating drugs in the biologics and biosimilar sector, continuous technological advancements, heightened approval rates of innovative devices by regulatory bodies, and an increased introduction of advanced devices for optimized dose administration are some of the key factors boosting the market growth.
An increased introduction of advanced devices for optimized dose administration is predicted to boost the market growth during the forecast period. The utilization of subcutaneous drug delivery devices has led to a decrease in dosage errors and the avoidance of needlestick injuries. Patients using devices with straightforward drug administration protocols exhibit improved treatment adherence. Consequently, the use of pain-free subcutaneous drug delivery devices can significantly contribute to the effective management of various chronic medical conditions. For instance, in January 2022, Innovation Zed, the authorized partner of SHL Medical for connected pen injector solutions, has revealed its intention to introduce InsulCheck DOSE. This connected accessory device converts conventional pen injectors into intelligent solutions, aiding in the monitoring of disease management regimens.
By product, pen injectors was the highest revenue-grossing segment in the global subcutaneous drug delivery devices market in 2023 owing to the straightforward product design, cost-effectiveness, and growing societal approval, coupled with a rise in product approvals. For instance, in February 2023, Tezspire (tezepelumab), a collaborative product of AstraZeneca and Amgen, has received approval in the United States for self-administration. The approval allows its use in a pre-filled, single-use pen for individuals aged 12 years and older who suffer from severe asthma. Additionally, wearable injectors is predicted to grow at the fastest CAGR during the forecast period owing to the surge in prescription of patch pumps or bolus injectors by physicians to administer high-viscosity & large-volume biologic drugs and growing emphasis on the development of digitally powered subcutaneous drug delivery devices.
By usability, reusable was the highest revenue-grossing segment in the global subcutaneous drug delivery devices market in 2023 owing to the increasing usage of cost-effective devices and a growing introduction of innovative platforms. For instance, in May 2022, Jabil Inc., a medical device firm, has introduced the Qfinity Autoinjector Platform, a versatile reusable drug delivery system with broad applicability. Additionally, Disposable is predicted to grow at the fastest CAGR during the forecast period owing to the increasing popularity of single-use drug delivery devices and a rise in awareness concerning the maintenance of sterility.
By disease indication, auto-immune disorder was the highest revenue-grossing segment in the global subcutaneous drug delivery devices market in 2023 owing to the increase in the incidence of autoimmune disorders, accompanied by advancements in research & development activities, and a rising number of regulatory approvals. For instance, in January 2023, MTD Group has disclosed that its affiliate, Pikdare S.p.A., has received FDA clearance for the DropSafe Sicura passive safety needle. This needle features a fully passive mechanism and is designed for the administration of vaccines and other medications into both the muscle and subcutaneous tissue. Additionally, oncology disorders is predicted to grow at the fastest CAGR during the forecast period owing to the incidence of cancer is on the rise, and there is a growing awareness of cancer treatment.
By distribution channel, retail pharmacies was the highest revenue-grossing segment in the global subcutaneous drug delivery devices market in 2023 owing to the rise in self-administration, increasing patient awareness, a heightened emphasis on favorable medical outcomes, and a surge in the approval of advanced devices. For instance, in October 2022, scPharmaceuticals, a pharmaceutical company, has received FDA approval for Furoscix (furosemide injection), marking the first and only self-administered, subcutaneous loop diuretic approved for the treatment of congestion in chronic heart failure for use at home. Additionally, online pharmacies is predicted to grow at the fastest CAGR during the forecast period owing to the deals provided by developers on diverse subcutaneous drug delivery devices, higher internet accessibility, the increasing prevalence of online pharmacy platforms, and convenient payment alternatives.
North America region is anticipated for the highest revenue share during the forecast period owing to an advanced healthcare infrastructure, a rising incidence of chronic diseases such as multiple sclerosis, cardiovascular diseases, diabetes, and arthritis, along with an uptick in research and development endeavors. For instance, in July 2023, Genentech, part of the Roche Group, disclosed positive results from the Phase III OCARINA II trial assessing Ocrevus (ocrelizumab) administered as a 10-minute subcutaneous injection twice a year. The study successfully achieved its primary and secondary objectives among patients with relapsing forms of multiple sclerosis or primary progressive multiple sclerosis (RMS or PPMS). Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in individuals diagnosed with diabetes, heightened awareness of diabetes management, a surge in healthcare spending, and a growing introduction of new products. For instance, in November 2023, Chugai Pharmaceutical Co., Ltd. has introduced the Phesgo combination for Subcutaneous Injection for the treatment of HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer that has progressed after chemotherapy and is not suitable for curative surgery. Phesgo is a combination of antineoplastic agents and an anti-HER2 humanized monoclonal antibody.
An increased introduction of advanced devices for optimized dose administration is predicted to boost the market growth during the forecast period. The utilization of subcutaneous drug delivery devices has led to a decrease in dosage errors and the avoidance of needlestick injuries. Patients using devices with straightforward drug administration protocols exhibit improved treatment adherence. Consequently, the use of pain-free subcutaneous drug delivery devices can significantly contribute to the effective management of various chronic medical conditions. For instance, in January 2022, Innovation Zed, the authorized partner of SHL Medical for connected pen injector solutions, has revealed its intention to introduce InsulCheck DOSE. This connected accessory device converts conventional pen injectors into intelligent solutions, aiding in the monitoring of disease management regimens.
By product, pen injectors was the highest revenue-grossing segment in the global subcutaneous drug delivery devices market in 2023 owing to the straightforward product design, cost-effectiveness, and growing societal approval, coupled with a rise in product approvals. For instance, in February 2023, Tezspire (tezepelumab), a collaborative product of AstraZeneca and Amgen, has received approval in the United States for self-administration. The approval allows its use in a pre-filled, single-use pen for individuals aged 12 years and older who suffer from severe asthma. Additionally, wearable injectors is predicted to grow at the fastest CAGR during the forecast period owing to the surge in prescription of patch pumps or bolus injectors by physicians to administer high-viscosity & large-volume biologic drugs and growing emphasis on the development of digitally powered subcutaneous drug delivery devices.
By usability, reusable was the highest revenue-grossing segment in the global subcutaneous drug delivery devices market in 2023 owing to the increasing usage of cost-effective devices and a growing introduction of innovative platforms. For instance, in May 2022, Jabil Inc., a medical device firm, has introduced the Qfinity Autoinjector Platform, a versatile reusable drug delivery system with broad applicability. Additionally, Disposable is predicted to grow at the fastest CAGR during the forecast period owing to the increasing popularity of single-use drug delivery devices and a rise in awareness concerning the maintenance of sterility.
By disease indication, auto-immune disorder was the highest revenue-grossing segment in the global subcutaneous drug delivery devices market in 2023 owing to the increase in the incidence of autoimmune disorders, accompanied by advancements in research & development activities, and a rising number of regulatory approvals. For instance, in January 2023, MTD Group has disclosed that its affiliate, Pikdare S.p.A., has received FDA clearance for the DropSafe Sicura passive safety needle. This needle features a fully passive mechanism and is designed for the administration of vaccines and other medications into both the muscle and subcutaneous tissue. Additionally, oncology disorders is predicted to grow at the fastest CAGR during the forecast period owing to the incidence of cancer is on the rise, and there is a growing awareness of cancer treatment.
By distribution channel, retail pharmacies was the highest revenue-grossing segment in the global subcutaneous drug delivery devices market in 2023 owing to the rise in self-administration, increasing patient awareness, a heightened emphasis on favorable medical outcomes, and a surge in the approval of advanced devices. For instance, in October 2022, scPharmaceuticals, a pharmaceutical company, has received FDA approval for Furoscix (furosemide injection), marking the first and only self-administered, subcutaneous loop diuretic approved for the treatment of congestion in chronic heart failure for use at home. Additionally, online pharmacies is predicted to grow at the fastest CAGR during the forecast period owing to the deals provided by developers on diverse subcutaneous drug delivery devices, higher internet accessibility, the increasing prevalence of online pharmacy platforms, and convenient payment alternatives.
North America region is anticipated for the highest revenue share during the forecast period owing to an advanced healthcare infrastructure, a rising incidence of chronic diseases such as multiple sclerosis, cardiovascular diseases, diabetes, and arthritis, along with an uptick in research and development endeavors. For instance, in July 2023, Genentech, part of the Roche Group, disclosed positive results from the Phase III OCARINA II trial assessing Ocrevus (ocrelizumab) administered as a 10-minute subcutaneous injection twice a year. The study successfully achieved its primary and secondary objectives among patients with relapsing forms of multiple sclerosis or primary progressive multiple sclerosis (RMS or PPMS). Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in individuals diagnosed with diabetes, heightened awareness of diabetes management, a surge in healthcare spending, and a growing introduction of new products. For instance, in November 2023, Chugai Pharmaceutical Co., Ltd. has introduced the Phesgo combination for Subcutaneous Injection for the treatment of HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer that has progressed after chemotherapy and is not suitable for curative surgery. Phesgo is a combination of antineoplastic agents and an anti-HER2 humanized monoclonal antibody.
Segmentation: Subcutaneous Drug Delivery Devices Market Report 2023 - 2034
Subcutaneous Drug Delivery Devices Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Prefilled Syringes
- Pen Injectors
- Auto-Injectors
- Needle-Free Injectors
- Wearable Injectors
Subcutaneous Drug Delivery Devices Market Analysis & Forecast by Usability 2023 - 2034 (Revenue USD Bn)
- Reusable
- Disposable
Subcutaneous Drug Delivery Devices Market Analysis & Forecast by Disease Indication 2023 - 2034 (Revenue USD Bn)
- Auto-Immune Disorders
- Neurological Disorders
- Oncology Disorders
- Hormonal Disorders
- Allergy & Infectious Disorders
- Ophthalmic Disorders
- Others
Subcutaneous Drug Delivery Devices Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Subcutaneous Drug Delivery Devices Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Subcutaneous Drug Delivery Devices Market: Product Estimates & Trend Analysis
8. Subcutaneous Drug Delivery Devices Market: Usability Estimates & Trend Analysis
9. Subcutaneous Drug Delivery Devices Market: Disease Indication Estimates & Trend Analysis
10. Subcutaneous Drug Delivery Devices Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Subcutaneous Drug Delivery Devices Market
13. Europe Global Subcutaneous Drug Delivery Devices Market
14. Asia Pacific Global Subcutaneous Drug Delivery Devices Market
15. Latin America Global Subcutaneous Drug Delivery Devices Market
16. MEA Global Subcutaneous Drug Delivery Devices Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Johnson & Johnson
- Medtronic Plc
- Insulet Corporation
- Novartis International AG
- Novo Nordisk A/S
- Teva Pharmaceutical Industries Ltd
- Amgen Inc.
- F. Hoffmann-La Roche AG.
- Eli Lilly and Company
- PharmaJet
- Merck & Co. Inc
- Inolife Sciences
- Becton Dickinson and Company
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 31.63 Billion |
| Forecasted Market Value ( USD | $ 94.58 Billion |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
